We evaluated two different diagnostic pathways incorporating two well characterized biomarkers that have previously been used to monitor lysosomal storage disease progression (ChT activity and CCL18/PARC concentration) alongside appraisals of clinical symptoms and NP-C SI assessments. The gene discussed is SLC5A7; the disease is lysosomal storage disease.